DIGIANDOMENICO ANTHONY - 28 Mar 2022 Form 4 Insider Report for ENDRA Life Sciences Inc. (NDRA)

Role
Director
Signature
/s/ Anthony DiGiandomenico by Mark Busch, attorney-in-fact
Issuer symbol
NDRA
Transactions as of
28 Mar 2022
Net transactions value
$0
Form type
4
Filing time
30 Mar 2022, 17:15:34 UTC
Previous filing
04 Jan 2022
Next filing
01 Feb 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NDRA Stock Options Award $0 +109,323 $0.000000 109,323 28 Mar 2022 Common Stock 109,323 $0.3800 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This stock option grant becomes exercisable in three equal annual installments beginning March 28, 2023.